首页> 外国专利> Pharmaceutical composition for prevention and treatment of chronic obstructive pulmonary disease comprising extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient

Pharmaceutical composition for prevention and treatment of chronic obstructive pulmonary disease comprising extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient

机译:用于预防和治疗慢性阻塞性肺疾病的药物组合物,其包含黑毛竹(Phyllostachys nigra Munro var)的提取物。无性病Stapf作为有效成分

摘要

The present invention relates to a pharmaceutical composition for the prevention and treatment of chronic obstructive pulmonary disease (COPD) comprising the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. Particularly, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can reduce the numbers of macrophages and neutrophils increased in bronchoalveolar lavage fluid (BALF) and is effective in preventing weight loss caused by chronic obstructive pulmonary disease and is effective in down-regulating significantly IL-6, TNF-±, IL-1², MCP-1, and MMP-12, which are rapidly increased in bronchoalveolar lavage fluid, intrapulmonary tissue, and serum according to the development of chronic obstructive pulmonary disease. In addition, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention has the effect of blocking the activation of NF-ºB signal in intrapulmonary tissue and significantly reduces inflammatory cells in the tissues around alveoli as well as significantly reduces the size of the enlarged alveola. Therefore, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can be effectively used as an active ingredient of medicines and health food for the prevention and treatment of chronic obstructive pulmonary disease.
机译:本发明涉及用于预防和治疗慢性阻塞性肺疾病(COPD)的药物组合物,其包含黑毛竹(Phyllostachys nigra Munro var)的提取物。 henosis Stapf为有效成分。特别是黑毛竹的提取物。本发明的无意识性Stapf可以减少支气管肺泡灌洗液(BALF)中增加的巨噬细胞和嗜中性粒细胞的数量,并且对于预防由慢性阻塞性肺疾病引起的体重减轻是有效的,并且对于显着下调IL-6,TNF-±有效。 ,IL-1²,MCP-1和MMP-12,随着慢性阻塞性肺疾病的发展,它们在支气管肺泡灌洗液,肺内组织和血清中迅速增加。另外,黑毛竹的提取物。本发明的无意识性Stapf具有阻断肺内组织中NF-κB信号的激活的作用,并且显着减少了肺泡周围组织中的炎性细胞,并且显着减小了增大的肺泡的大小。因此,黑毛楠提取物。本发明的henosis Stapf可有效地用作预防和治疗慢性阻塞性肺疾病的药物和保健食品的活性成分。

著录项

  • 公开/公告号KR101427290B1

    专利类型

  • 公开/公告日2014-08-06

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20120029398

  • 发明设计人 김진주;고은정;이의정;

    申请日2012-03-22

  • 分类号A61K36/899;A61P11;

  • 国家 KR

  • 入库时间 2022-08-21 15:40:23

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号